BACKGROUND: Amino (N)-terminal pro-brain natriuretic peptide (NT-proBNP) testing is useful for diagnostic and prognostic evaluation in patients with dyspnea. An inverse relationship between body mass index (BMI); (calculated as weight in kilograms divided by height in meters squared) and NT-proBNP concentrations has been described. METHODS: One thousand one hundred three patients presenting to the emergency department with acute dyspnea underwent analysis. Patients were classified into the following 3 BMI categories: lean (<25.0), overweight (25.0-29.9), and obese (>/=30.0). RESULTS: The NT-proBNP concentrations in the overweight and obese groups were significantly lower than in the lean patients, regardless of the presence of acute heart failure (P<.001). The positive likelihood ratio for an NT-proBNP-based diagnosis of acute heart failure was 5.3 for a BMI lower than 25.0, 13.3 for a BMI of 25.0 to 29.9, and 7.5 for a BMI of 30.0 or higher. A cut point of 300 ng/L had very low negative likelihood ratios in all 3 BMI categories (0.02, 0.03, and 0.08, respectively). Among decedents, the NT-proBNP concentrations were lower in the overweight and obese patients compared with the lean subjects (P<.001). Nonetheless, a single cut point of 986 ng/L strongly predicted 1-year mortality across the 3 BMI strata, regardless of the presence of acute heart failure (hazard ratios, 2.22, 3.06, and 3.69 for BMIs of <25.0, 25.0-29.9, and >/=30.0, respectively; all P<.004); the risk associated with a high NT-proBNP concentration was detected early and was sustained to a year after baseline in all 3 BMI strata (all P<.001). CONCLUSIONS: In patients with and without acute heart failure, the NT-proBNP concentrations are relatively lower in overweight and obese patients with acute dyspnea. Despite this, the NT-proBNP concentration retains its diagnostic and prognostic capacity across all BMI categories.
BACKGROUND: Amino (N)-terminal pro-brain natriuretic peptide (NT-proBNP) testing is useful for diagnostic and prognostic evaluation in patients with dyspnea. An inverse relationship between body mass index (BMI); (calculated as weight in kilograms divided by height in meters squared) and NT-proBNP concentrations has been described. METHODS: One thousand one hundred three patients presenting to the emergency department with acute dyspnea underwent analysis. Patients were classified into the following 3 BMI categories: lean (<25.0), overweight (25.0-29.9), and obese (>/=30.0). RESULTS: The NT-proBNP concentrations in the overweight and obese groups were significantly lower than in the lean patients, regardless of the presence of acute heart failure (P<.001). The positive likelihood ratio for an NT-proBNP-based diagnosis of acute heart failure was 5.3 for a BMI lower than 25.0, 13.3 for a BMI of 25.0 to 29.9, and 7.5 for a BMI of 30.0 or higher. A cut point of 300 ng/L had very low negative likelihood ratios in all 3 BMI categories (0.02, 0.03, and 0.08, respectively). Among decedents, the NT-proBNP concentrations were lower in the overweight and obesepatients compared with the lean subjects (P<.001). Nonetheless, a single cut point of 986 ng/L strongly predicted 1-year mortality across the 3 BMI strata, regardless of the presence of acute heart failure (hazard ratios, 2.22, 3.06, and 3.69 for BMIs of <25.0, 25.0-29.9, and >/=30.0, respectively; all P<.004); the risk associated with a high NT-proBNP concentration was detected early and was sustained to a year after baseline in all 3 BMI strata (all P<.001). CONCLUSIONS: In patients with and without acute heart failure, the NT-proBNP concentrations are relatively lower in overweight and obesepatients with acute dyspnea. Despite this, the NT-proBNP concentration retains its diagnostic and prognostic capacity across all BMI categories.
Authors: Navin Suthahar; Wouter C Meijers; Jennifer E Ho; Ron T Gansevoort; Adriaan A Voors; Peter van der Meer; Stephan J L Bakker; Stephane Heymans; Vanessa van Empel; Blanche Schroen; Pim van der Harst; Dirk J van Veldhuisen; Rudolf A de Boer Journal: Eur J Heart Fail Date: 2018-06-01 Impact factor: 15.534
Authors: Hanna K Gaggin; Arianna M Belcher; Parul U Gandhi; Nasrien E Ibrahim; James L Januzzi Journal: J Cardiovasc Transl Res Date: 2016-09-08 Impact factor: 4.132
Authors: Stephen A Hill; Ronald A Booth; P Lina Santaguida; Andrew Don-Wauchope; Judy A Brown; Mark Oremus; Usman Ali; Amy Bustamam; Nazmul Sohel; Robert McKelvie; Cynthia Balion; Parminder Raina Journal: Heart Fail Rev Date: 2014-08 Impact factor: 4.214
Authors: Juliana Jensen; Li-Ping Ma; Michael L X Fu; David Svaninger; Per-Arne Lundberg; Ola Hammarsten Journal: Clin Res Cardiol Date: 2010-03-13 Impact factor: 5.460
Authors: Umair Khalid; Lisa Miller Wruck; Pedro Miguel Quibrera; Biykem Bozkurt; Vijay Nambi; Salim S Virani; Hani Jneid; Sunil Agarwal; Patricia P Chang; Laura Loehr; Sukhdeep Singh Basra; Wayne Rosamond; Christie M Ballantyne; Anita Deswal Journal: Int J Cardiol Date: 2017-01-31 Impact factor: 4.164
Authors: Benjamin W Van Tassell; Cory R Trankle; Justin M Canada; Salvatore Carbone; Leo Buckley; Dinesh Kadariya; Marco G Del Buono; Hayley Billingsley; George Wohlford; Michele Viscusi; Claudia Oddi-Erdle; Nayef A Abouzaki; Dave Dixon; Giuseppe Biondi-Zoccai; Ross Arena; Antonio Abbate Journal: Circ Heart Fail Date: 2018-08 Impact factor: 8.790